Background-Hypoglycemia is associated with increased cardiovascular mortality, but the reason for this association is poorly understood. We tested the hypothesis that the myocardial blood flow reserve (MBFR) is decreased during hypoglycemia using myocardial contrast echocardiography in patients with type 1 diabetes mellitus (DM) and in healthy control subjects. Methods and Results-Twenty-eight volunteers with DM and 19 control subjects underwent hyperinsulinemic clamps with maintained sequential hyperinsulinemic euglycemia (plasma glucose, 90 mg/dL [5.0 mmol/L]) followed by hyperinsulinemic hypoglycemia (plasma glucose, 50 mg/dL [2.8 mmol/L]) for 60 minutes each. Low-power real-time myocardial contrast echocardiography was performed with flash impulse imaging using low-dose dipyridamole stress at baseline and during hyperinsulinemic euglycemia and hyperinsulinemic hypoglycemia. In control subjects, MBFR increased during hyperinsulinemic euglycemia by 0.57 U (22%) above baseline (B coefficient, 0.57; 95% confidence interval, 0.38 to 0.75; PϽ0.0001) and decreased during hyperinsulinemic hypoglycemia by 0.36 U (14%) below baseline values (B coefficient, Ϫ0.36; 95% confidence interval, Ϫ0.50 to Ϫ0.23; PϽ0.0001). Although MBFR was lower in patients with DM at baseline by 0.37 U (14%; B coefficient, Ϫ0.37; 95% confidence interval, Ϫ0.55 to Ϫ0.19; Pϭ0.0002) compared with control subjects at baseline, the subsequent changes in MBFR during hyperinsulinemic euglycemia and hyperinsulinemic hypoglycemia in DM patients were similar to that observed in control subjects. Finally, the presence of microvascular complications in the patients with DM was associated with a reduction in MBFR of 0.52 U (24%; B coefficient, Ϫ0.52; 95% confidence interval, Ϫ0.70 to Ϫ0.34; PϽ0.0001). Conclusions-Hypoglycemia decreases MBFR in both healthy humans and patients with DM. This finding may explain the association between hypoglycemia and increased cardiovascular mortality in susceptible individuals. (Circulation. 2011;124:1548-1556.) The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/
S everal studies have shown that hypoglycemia is associated with an increase in cardiovascular mortality (CVM). [1] [2] [3] [4] [5] [6] This association has been demonstrated in people with and without established coronary artery disease. [1] [2] [3] Importantly, patients with acute coronary syndromes appear to have worse short-and long-term outcomes if they experience hypoglycemia in the acute phase of their presentation. [2] [3] [4] For example, in patients with diabetes mellitus (DM) and acute coronary syndromes, hypoglycemia within 48 hours of their admission was associated with a 2-fold increase in all-cause mortality over a 2-year follow-up. 2 Similarly, Pinto et al 3 showed that patients with ST-segment-elevation myocardial infarction and an admission blood glucose Ͻ4.5 mmol/L had a 3-fold increased rate of adverse outcomes (defined as 30-day mortality and myocardial infarction). Furthermore, in the same study, patients with DM had an 18-fold increased risk of adverse cardiac outcomes. Subsequently, a more recent study showed that in patients after myocardial infarction, spontaneous hypoglycemia was associated with a 2-fold increase in in-hospital mortality. 4
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Insulin, under euglycemic conditions, has important beneficial effects on the vascular tone by inducing nitric oxidemediated vasodilatation. 7 Studies on healthy humans and patients with DM show that insulin causes a marked increase in myocardial blood flow (MBF) and MBF reserve (MBFR) during euglycemia. 8, 9 In contrast, the mechanisms by which hypoglycemia adversely affects the cardiovascular system are unclear. Hypoglycemia has been associated with angina and, importantly, has been shown to increase the size of a myocardial infarct. 10, 11 Furthermore, low blood glucose also encourages a hypercoagulant state resulting from an increase in plasma concentrations of coagulation factors and by promoting platelet aggregation. 12, 13 Myocardial contrast echocardiography (MCE) is an established technique used in the noninvasive quantification of MBFR with an accuracy similar to that of positron emission tomography and coronary Doppler flow wire measurements. 14, 15 MBFR is calculated as the ratio of peak MBF to resting MBF. 14 In the absence of flow-limiting coronary artery disease, an MBFR Ͻ2.0 is indicative of underlying endothelial dysfunction. 16 Furthermore, MBFR has been shown to be an independent predictor of CVM in diabetic and nondiabetic patients with normal stress echocardiograms and in patients after acute coronary syndromes. [17] [18] [19] We hypothesized that hypoglycemia would decrease the MBFR (measured by MCE) using a 1-step hyperinsulinemic clamp technique to induce hypoglycemia in patients with type 1 DM and in healthy control subjects.
Methods

Subjects
Twenty-eight subjects with type 1 DM (group DM) participated in the study after approval of the local research ethical committee. In addition, 19 healthy volunteers (group C) acted as control subjects. All volunteers underwent testing of MBF by MCE. Assessment of MBF was undertaken with an insulin clamp at 3 stages: at baseline, during hyperinsulinemic euglycemia (HE), and during hyperinsulinemic hypoglycemia (HH). During each stage, all volunteers underwent measurement of MBF during 2 states: at rest and after dipyridamole-induced stress.
None of the volunteers were active smokers or had a history of hypertension, coronary artery disease, or underlying lipid disorders. All volunteers had normal exercise stress echocardiograms. Within the DM group, 8 volunteers had evidence of microvascular complications (see the online-only Data Supplement). All volunteers provided written informed consent.
Hyperinsulinemic Clamps
Volunteers were admitted after an overnight fast. The overall study scheme is shown in Figure 1A and 1B. Written instructions were provided to avoid caffeine-containing products and alcohol for Ͼ12 hours. In the DM group, a standard sliding-scale insulin was begun to keep glucose levels close to 90 mg/dL (5.0 mmol/L). After a 30to 40-minute rest period, baseline plasma glucose was determined, and the hyperinsulinemic clamp was begun. 20 Insulin was infused at 3 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 for 4 minutes, followed by 2 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 for a further 3 minutes, after which the infusion rate was maintained at 1.5 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 . Hyperinsulinemic euglycemia (90 mg/dL [5.0 mmol/L]) was maintained for 60 minutes after an initial 30-minute stabilization period. Glucose levels were subsequently reduced over a 30-minute period by decreasing the 20% (wt/vol) dextrose (Baxter Healthcare, Thetford, Norfolk, UK) infusion rate, and symptomatic hypoglycemia (50 mg/dL [2.8 mmol/L]) was induced (see the online-only Data Supplement). The glucose concentrations were maintained for a further 60 minutes (HH), after which insulin infusion was terminated and normoglycemia was restored.
Myocardial Contrast Echocardiography
We performed MCE using a commercial ultrasound machine iE33 (Philips Medical Systems, Best, the Netherlands) and SonoVue (Bracco Research SA, Geneva, Switzerland) as the contrast agent as previously described. 21 Real-time images were recorded within 3 to 4 minutes in the 3 apical views (apical 4-chamber, apical 2-chamber, and apical 3-chamber views) with low-power settings at a mechanical index of 0.1. The focus was set at the mitral valve level. SonoVue was initially started at 60 mL/h through the left anterograde cannula with the VueJect infusion syringe pump (BR-INF 100, Bracco Research, SA), which gently rotates and maintains the contrast agent in a suspension. Thereafter, the rate was set between 48 and 60 mL/h to maximize image quality with minimal attenuation. Once optimized, the machine settings were held constant throughout each participant study. Flash-impulse imaging at a high mechanical index (1.0) was performed to achieve complete myocardial bubble destruction, after which 10 end-systolic frames were recorded digitally in each apical view. After the resting images were acquired, dipyridamole was infused at 0.56 mg/kg over a 4-minute period. After an interval of 2 minutes, poststress images were recorded within 3 to 4 minutes. This entire sequence took 14 minutes ( Figure 1B ). The MCE studies were performed at baseline before insulin infusion and during HE and HH ( Figure 1A ). Continuous ECG monitoring was undertaken, and blood pressure was recorded before and after stress during each study.
Analytic Methods
Quantitative MCE analysis was performed offline with standard commercially available software, QLab version 7.0 (Q-Laboratory, Philips Medical Systems). Quantitative assessment of myocardial perfusion was performed for 10 consecutive end-systolic frames after microbubble destruction. A region of interest was placed over the entire thickness of the myocardium, and particular care was taken to exclude high-intensity epicardial and endocardial borders by manu- ally moving the region of interest between each frame (see Figure 2 ). Background-subtracted plots of peak myocardial contrast intensity (representing myocardial blood volume A, dB) versus pulsing intervals (representing time) were automatically constructed by QLab software to fit the monoexponential function conventional equation: yϭA (1Ϫe Ϫ␤t ). 14 From these plots, the slope of the replenishment curve was determined (representing myocardial blood velocity ␤, dB/s). The product of A and ␤ yielded resting MBF (dB 2 /s) and postdipyridamole MBF (peak MBF, dB 2 /s), respectively ( Figure I in the online-only Data Supplement). 14 We calculated MBFR by the ratio of peak MBF to resting MBF. 14 Furthermore, MBFR was calculated by dividing the peak MBF by the resting MBF of the same segment at each of the 3 time frames (baseline, HE, and HH). The basal segments were not included in the analysis because of contrast attenuation. 22 The remaining 10 mid and apical cardiac segments were analyzed as shown in Figure 2 . 22 A segment was not included in the analysis if there was artifact, inadequate microbubble destruction, attenuation, or a wide variation in contrast intensity to minimize errors. The average number of analyzable segments for baseline, HE, and HH was 6 for each. All studies were reanalyzed blindly for intraobserver variability, and for interobserver agreement, 100 myocardial segments were randomly analyzed by another observer (K.G.) who was blinded to the sequence of the studies. The intraobserver and interobserver variabilities were 7.7% and 8.2%, respectively.
Venous samples were taken at baseline and every 30 minutes thereafter (7 samples in total) for determination of plasma endothelin-1 (ET-1) and epinephrine levels, as well as serum high-sensitivity C-reactive protein and insulin levels. All assays were performed in duplicate by a single observer (S.Z.) who was blinded to the hemodynamic and MCE data. Plasma ET-1 levels were measured with a quantitative sandwich enzyme immunoassay (QuantiGlo ELISA, R&D Systems, Abingdon, UK) according to the manufacturer's instructions. Intra-assay and interassay coefficients of variation were 3.4% and 8.9%, respectively, with a cross-reactivity of Ͻ0.02% for all human big ETs, 9% for ET-3, and 51% for ET-2. Plasma high-sensitivity C-reactive protein was determined with a particleenhanced immunoassay with an interassay coefficient of variation Ͻ10% (Roche Diagnostics, Burgess Hill, UK). Plasma epinephrine levels were measured after extraction and acetylation by competitive immunoassay (Labor Diagnostika Nord, Nordhorn, Germany). Both intra-assay and interassay coefficients of variation were Ͻ15%. Serum insulin concentrations were measured with electrochemiluminescence immunoassay (Roche Diagnostics, Burgess Hill, UK). The assay shows minimal cross-reactivity with proinsulin or recombinant insulin analogs, and the intra-assay and interassay coefficients of variation were Ͻ2% and Ͻ5%, respectively.
Statistical Analysis
All data are represented as meanϮSD except ET-1 and highsensitivity C-reactive protein values, which are presented as median (interquartile range).
For MBF, ␤, and A, the influence of measurement stage, stress state, and the presence of DM was assessed via mixed-effects regression modeling (to reflect the intraclass correlation resulting from repeated measurements made on each subject). For each of these 3 outcomes, a mixed-effects model was fitted in which the main effects of stage, stress state, and DM (together with all of their possible interactions) were assessed. Modeling was performed with the MIXED procedure in SAS software (version 9.2). Interpretation of these models is described in the online-only Data Supplement.
In addition to yielding regression parameter estimates, the models were used to estimate mean values for each combination of effects (via the LSMEANS option in the MIXED procedure) and to test for selected differences in these means. With 12 effects combinations (ie, 3 stagesϫ2 stress statesϫ2 diabetes states [present/absent]), the maximum number of possible between-group differences was 66. It was fully recognized that formal testing of between-group differences under these conditions was justified only when there was some a priori reason to anticipate the presence of an effect of interest and under the strict understanding that the primary purpose of such testing was the generation of hypotheses for future research rather For the main outcome (MBFR), the concept of stress state was not applicable. Consequently, this outcome was investigated via a further mixed-effects regression model in which MBFR was predicted by the main effects of measurement stage and of DM together with that of their interaction, by age, and by the subject's systolic blood pressure.
Results
Subject Characteristics
The baseline characteristics of the 19 healthy volunteers (group C) and 28 volunteers with DM are summarized in Table 1 .
Hemodynamic Data
Throughout the clamp, resting heart rate, resting systolic blood pressure, resting diastolic blood pressure, and resting rate-pressure product were similar in groups C and DM ( Table I in 
Myocardial Contrast Echocardiography-Derived Measurements
Myocardial Blood Volume
Mean myocardial blood volumes and 95% confidence intervals (95% CIs) at rest (A r ) and during dipyridamole-induced stress (A d ) are shown at baseline and during HE and HH in Table 2 . Table 3 shows the mixed-effect regression modeling testing the effect of stage, state, DM, and their interactions on A r and A d .
There was a significant increase in A d in group C at baseline by 2.7 dB (PϽ0.0001), as shown in Table 3 . In addition, there was marginal evidence that A d was decreased during HH by 1.4 dB compared with baseline (Pϭ0.068). Furthermore, the presence of DM did not affect either A r or A d at the baseline stage (Pϭ0.25 and Pϭ0.65, respectively). However, there was a suggestion that A d was increased in group DM during HH compared with group C by 1.9 dB (Pϭ0.056).
Myocardial Blood Velocity
Mean myocardial blood velocities and 95% CIs at rest (␤ r ) and during dipyridamole-induced stress (␤ d ) are shown at baseline and during HE and HH in Table 4 . Table 5 shows the mixed effect regression modeling testing the effect of stage, state, DM and their interactions on ␤ r and ␤ d .
There was a significant increase in ␤ d in group C at baseline by 1.08 dB/s (PϽ0.0001), as shown in Table 5 . During HE, ␤ d was further increased in group C compared with baseline values by 0.37 dB/s (PϽ0.0001). However, during HH, ␤ d declined and was not different from baseline stress values (Pϭ0.28). In group DM, ␤ r was significantly elevated compared with group C at baseline by 0.11 dB/s (Pϭ0.035). Importantly, at baseline, ␤ d was significantly decreased in group DM compared with group C by 0.27 dB/s (Pϭ0.005).
In group DM, during HE and HH, a similar effect on ␤ d was observed compared with group C with no significant differences between the 2 groups at each stage.
Myocardial Blood Flow
Mean MBFs and 95% CIs at rest (resting MBF) and during dipyridamole-induced stress (peak MBF) are shown at baseline and during HE and HH in Table 6 . Table 7 shows the mixed-effect regression modeling testing the effect of stage, state, DM, and their interactions on MBF.
In group C, peak MBF was significantly increased compared with resting MBF at baseline by 26.5 dB 2 /s (PϽ0.0001) as shown in Table 7 . During HE, peak MBF was further increased in group C above baseline peak values by 11.6 dB 2 /s (PϽ0.0001). However, during HH, peak MBF declined and was not significantly different from baseline peak MBF values (Pϭ0.20).
The resting MBF was significantly higher in group DM compared with group C at baseline by 2.6 dB 2 /s (Pϭ0.015). There was no significant difference in the resting MBF values between the 2 groups at HE or HH. In group DM, peak MBF was significantly decreased compared with group C at baseline by 6.0 dB 2 /s (Pϭ0.006). In group DM, during HE and HH, a similar effect on peak MBF was observed compared with group C with no significant differences between the 2 groups at each stage.
Myocardial Blood Flow Reserve
We tested the effect of measurement stage, age, presence of DM, and systolic blood pressure on MBFR using regression modeling ( Table 8 and Figure 3 ). In Table 8 , the intercept of Table 4 Stage is baseline, hyperinsulinemic euglycemia (HE), or hyperinsulinemic hypoglycemia (HH). State is resting (resting blood velocityϭ␤ r ) or during dipyridamole stress (peakϭ␤ d ). Values are means (95% confidence intervals). 
. Myocardial Blood Velocity (␤) at Rest and After Dipyridamole-Induced Stress at Baseline and During Hyperinsulinemic Euglycemia and Hyperinsulinemic Hypoglycemia
Table 5. Mixed-Effect Regression Model Showing the Effect of Measurement Stage (at Baseline, During Hyperinsulinemic Euglycemia, and During Hyperinsulinemic Hypoglycemia), Presence of Diabetes Mellitus, and Stress State (Rest Versus After Dipyridamole-Induced Stress) on Myocardial Blood Velocity (␤)
Effect of Microvascular Complications on Myocardial Blood Flow Reserve
The mixed-model method was applied to explore whether the presence of microvascular complications in people with DM was predictive of a decreased MBFR. A mixed model was fitted (using data for subjects with DM only) in which MBFR was predicted by stage, the presence of microvascular complications, and a term representing the stage/complications interaction. This mixed model ( Stage is baseline, hyperinsulinemic euglycemia (HE), or hyperinsulinemic hypoglycemia (HH). State is resting myocardial blood flow or during dipyridamole stress (myocardial blood flow MBF). Values are means (95% confidence intervals). 
Changes in Concentrations of Endothelin-1, High-Sensitivity C-Reactive Protein, Epinephrine, and Serum Insulin During the Hyperinsulinemic Clamp
To explore further the explanation for the decrease in MBFR during HH, we measured plasma ET-1 (as a potent vasoconstrictor) and serum high-sensitivity C-reactive protein (as a nonspecific marker of inflammation; Table III in the onlineonly Data Supplement). Plasma ET-1 concentrations at baseline were 0.19 pg/mL in control subjects and 1.44 pg/mL in the group with DM (PϽ0.0001). In the group with DM, ET-1 remained markedly increased throughout the whole clamp, and there was a suggestion that ET-1 levels increased toward the end of the HH clamp in control subjects. Serum highsensitivity C-reactive protein concentrations were not different between the 2 groups and did not change during the study. We also measured serum insulin levels (in view of the hyperinsulinemic clamp) and plasma epinephrine levels (to assess the counterregulatory response to hypoglycemia) in all individuals ( Table III in the online-only Data Supplement). Serum insulin concentrations at baseline were 43Ϯ23 pmol/L in control subjects and 208.3Ϯ207 pmol/L in the group with DM. The plasma epinephrine levels were similar between the 2 groups at all stages.
Discussion
We have shown for the first time that insulin-induced hypoglycemia (HH) decreases the MBFR in both patients with type 1 DM and healthy subjects. We have demonstrated that in healthy controls during HE, insulin induced a marked increase in peak MBF and MBFR, whereas hypoglycemia led to a decline in peak MBF and a decrease in MBFR. Importantly, patients with type 1 DM behaved in a manner similar to the healthy control subjects (Figure 3 ) in the presence of HE and HH, although the presence of DM was associated with a more marked reduction in MBFR at baseline. The reduction in peak MBF during HH appeared to be due to a decrease in myocardial blood velocity rather than blood volume. We have also shown that the presence of microvascular complications is associated with a decrease in MBFR in patients with type 1 DM. Therefore, the overall effect of hypoglycemia during HH is to suppress peak MBF, thereby mitigating the vasodilatory action of hyperinsulinemia that occurs during physiological glucose concentrations. A significant amount of evidence has associated hypoglycemia with increased CVM. [1] [2] [3] 6, 23, 24 In a study including 40 069 patients, fasting hypoglycemia was independently associated with a 3-fold increased risk in CVM after a mean follow-up of 8 years. 1 Pinto et al 3 observed that after ST-segment-elevation myocardial infarction, patients with a Thrombolysis in Myocardial Infarction risk score Ͼ4 and concomitant hypoglycemia had a Ͼ11-fold increased risk of death within 30 days compared with those with normal glucose levels. Furthermore, another study including patients with established coronary artery disease showed that fasting hypoglycemia was associated with a 2-fold increase in all-cause mortality. 23 A subsequent study observed a 16% increase in the relative risk of CVM in the group receiving insulin therapy on admission to intensive care. 6 Although this finding was unexplained, there was a 13-fold increased prevalence of severe hypoglycemia in the patients on insulin therapy compared with patients receiving conventional therapy. More recently, another study has demonstrated that fasting hypoglycemia was associated with a 33% increase in 3-year mortality rates in a cohort of 1854 elderly patients after an acute myocardial infarction. 24 This negative impact on survival was more pronounced in the subgroups with DM and those requiring coronary artery bypass grafting with a 2-and 3-fold increase in 3-year mortality rates, respectively. This evidence suggests that hypoglycemia is associated with shortand long-term adverse outcomes; however, the pathophysiological mechanisms are still ill defined and may vary.
Over the past few decades, several anecdotal case reports have associated hypoglycemia with episodes of angina and myocardial infarction. [25] [26] [27] Although a direct causal link has not been established, animal studies have demonstrated that hypoglycemia can increase myocardial infarct size by Ͼ40%. 11 Furthermore, in patients with DM and coexisting coronary artery disease, hypoglycemia was associated with a third of all episodes of angina and corresponding ischemic ECG changes. 10 The endothelium is a highly biologically active single cell layer responsible for the release of several substances, the most important of which are nitric oxide and ET-1. 28,29 A 21-amino acid peptide, ET-1 is the most potent vasoconstrictor but is identified in humans with a plasma half-life of 4 to 7 minutes. 30, 31 It induces its predominant vasoconstrictive effect by acting on receptors located on vascular smooth muscle cells and fibroblasts. This reduces nitric oxide bioavailability by either decreasing its production (caveolin-1-mediated inhibition of endothelial nitric oxide synthase activity) or increasing its degradation (via formation of oxygen radicals). 32 One recent study demonstrated that direct infusion of ET-1 into the coronary sinus of 6 humans decreased the coronary blood flow in a dose-related manner by up to 25%. 33 In addition, ET-1 levels have been shown to be the strongest predictor of no reflow after primary angioplasty. 34 Several disease states have been shown to be associated with endothelial dysfunction (an imbalance between the bioavailability of nitric oxide and ET-1). Examples include atherosclerosis, pulmonary arterial hypertension, DM, and myocardial ischemia. 29 Acute hypoglycemia has also been shown to increase ET-1 concentrations. 37 Wright and coworkers 37 demonstrated that ET-1 levels in patients with type 1 DM rose by almost 70% above baseline values 1 hour after insulin-induced hypoglycemia. In our study, although baseline ET-1 levels were Ϸ7-fold higher in the DM group compared with control subjects, the effect of HH versus HE on ET-1 is uncertain. We suggest that further work is needed specifically to elucidate the effects of more prolonged periods of hypoglycemia on ET-1 expression.
It is also plausible that other effects of hypoglycemia may have a deleterious impact on MBFR besides increases in ET-1. Hypoglycemia induces a hypercoagulant state in humans via increased platelet aggregation and changes in plasma concentrations of coagulation factors. 12, 13, 38, 39 For example, it has been shown that factor VIII was increased 2-fold after 30 minutes of hypoglycemia. 13 Hypoglycemia may also be responsible for initiating an inflammatory response. In 1 study, hypoglycemia was associated with a 3-fold increase in the neutrophil count and an elevation in neutrophil elastase, a potent proteolytic enzyme. 39 Long-QT syndrome is well recognized as being associated with an increased risk of sudden cardiac death. 40 More worryingly, acute hypoglycemia has been demonstrated to produce prolongation of the corrected QT interval by up to 35% in patients with type 1 DM, with values reaching Ͼ550 milliseconds. 41, 42 Interestingly, this change seems to be attributed predominantly to a surge in catecholamine levels and is independent of electrolyte imbalance. 43 Finally, prolonged hypoglycemia can have a detrimental effect on cardiac metabolism because of the inability of the heart to use glucose, the preferred substrate instead of fatty acids (during acute myocardial ischemia), after exhaustion of myocardial glycogen reserves. 44 In light of our findings, it is plausible to suggest that hypoglycemia, by causing a decrease in MBFR, may increase the risk of CVM in susceptible individuals.
Limitations
Although dipyridamole was used 3 times in succession with our study protocol ( Figure 1A and 1B) , we consider that the repeated use of dipyridamole was unlikely to artifactually influence our results (see the online-only Data Supplement). We did not calculate absolute myocardial perfusion values because all settings and infusion parameters, once optimized at the start of each patient study, were kept constant for the rest of that individual procedure. We deliberately did not randomize the sequence of HE and HH because this allowed individuals to act as their own controls, permitting constant insulin levels, contrast infusion rates, and ultrasound machine settings.
Conclusions
This study has shown that insulin-induced hypoglycemia is associated with a decrease in MBFR in healthy control subjects as a result of a reduction in peak MBF and that patients with type 1 DM behave in a similar manner. In contrast, insulin infusion at normal plasma glucose concentrations is associated with an increase in MBFR caused by an increase in peak MBF. Exploratory analyses suggest that the presence of DM and microvascular complications are inde-pendently associated with MBFR during HH. We speculate from our results that alterations in MBFR may explain the observed association between hypoglycemia and increased CVM in susceptible individuals.
